Quality-of-life assessment in advanced lung cancer: Considerations for evaluation in patients receiving chemotherapy

Lung Cancer

Volumn 46, Issue SUPPL. 2, 2004, Pages

  Gralla, Richard J ^a   Thatcher, Nick ^b  

^a New York Lung Cancer Alliance   (United States)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Docetaxel; Non small cell lung cancer; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM; VINDESINE;

ADVANCED CANCER; ANEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; NEPHROTOXICITY; NEUTROPENIA; PAIN ASSESSMENT; PERFORMANCE; PHYSICAL CAPACITY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SELF REPORT; SOCIAL ASPECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VALIDATION PROCESS; WEIGHT REDUCTION;

EID: 13244288025     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(04)80040-0     Document Type: Article

References (21)

1. Ganz P.A., Lee J.J., and Siau J. Quality of life assessments: an independent prognostic variable for survival in lung cancer Cancer 67 1999 3131 3135
2. Buccheri G.F., Ferrigno D., and Tamburini M. The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancer Lung Cancer 12 1995 45 58
3. Sen S., Gupchup G., and Thomas J. III Selecting among healthrelated quality-of-life instruments Am J Health-Syst Pharm 56 1999 1965 1973
4. Cella D., and Webster K. Linking outcome management to quality-of-life measurement Oncology 11 1997 232 235
5. Hollen P., Gralla R., and Kris M. Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LOSS) Eur J Cancer 29A suppl 1 1993 S51 S58
6. Hollen P.J., Gralla R.J., Kris M.G., and Cox C. Quality of life during clinical trials: Conceptual model for the Lung Cancer Symptom Scale (LCSS) Support Care Cancer 2 1994 213 222
7. Hollen P.J., and Gralla R.J. Comparison of instruments for measuring quality of life in patients with lung cancer Semin Oncol 23 suppl 5 1996 31 40
8. Cella D., Chang C., and Lai J. Advances in quality of life measurements in oncology patients Semin Oncol 29 suppl 8 2002 60 68
9. Abstract 1346 Perrone F., Gridelli C., and Cigolari S. Baseline assessment of quality of life (QOL) is a strong prognostic factor for survival of elderly patients with advanced non-small cell lungcancer (NSCLC). A secondary analysis of the MILES study Proc Am Soc Clin Oncol 21 2002 337a
10. Eton D.T., Fairclough D.L., and Cella D. Early change in patientreported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results f rom Eastern Cooperative Oncology Group Study 5592 J Clin Oncol 21 2003 1536 1543
11. Fossella F., Pereira J., and von Pawel J. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group J Clin Oncol 21 2003 3016 3024
12. Abstract 1196 Gralla R.J., Rodrigues J., and Von Pawel J. Prospective analysis of quality of life (QOL) in a randomized multinational phase III study comparing docetaxel (D) plus either cisplatin (C) or carboplatin (Cb) with vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 21 2002 310a
13. Abstract 2680 Monnier A., Zatloukal P., and Siffnerova E. Docetaxel (D) versus vinorelbine-cisplatin (VC) as front line treatment for patients with advanced non-small cell lung cancer (NSCLC) and with a normal level of serum alpha 1 acid glycoprotein (AAG): additional data on quality of life (QOL). Preliminary results Proc Am Soc Clin Oncol 22 2003 666
14. Kubota K., Watanabe K., and Kunitoh H. Phase III randomized trial of docetaxel-cisplatin versus vindesine-cisplatin with stage IV non-small-cell lung cancer J Clin Oncol 22 2004 254 261
15. Abstract 1165 Gridelli C., Shepherd F., and Perrone F. Gemvin III: a phase III study of gemcitabine plus vinorelbine (GV) compared to cisplatin plus vinorelbine or gemcitabine chemotherapy (PCT) forstage IIIb or IV non-small cell lung cancer (NSCLC): an Italo-Canadian study Proc Am Soc Clin Oncol 21 2002 292a
16. Shepherd F.A., Dancey J., and Ramlau R. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated withplatinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
17. Dancey J., Shepherd F.A., Gralla R.J., and Kim Y.S. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated withplatinum-based chemotherapy: results of a prospective, randomized phase III trial Lung Cancer 43 2004 183 194
18. Roszkowski K., Pluzanska A., and Krzakowski M. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients withmetastatic or nonresectable localized non-small cell lung cancer (NSCLC) Lung Cancer 27 2000 145 157
19. Scagliotti G.V., De Marinis F., and Rinaldi M. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 2002 4285 4291
20. Kelly K., Crowley J., and Bunn P.A. Jr Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218
21. Bonomi P., Kim K., and Fairclough D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined withcisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial J Clin Oncol 18 2000 623 631